Reach Us +44-1235-425476
FDA/EMA Current Thinking On Total Evidence For Development Of Biosimilars | 70767
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

FDA/EMA current thinking on total evidence for development of biosimilars

8th Asian Biologics and Biosimilars Congress

Kamali Chance

Quintiles IMS, USA

Keynote: J Bioanal Biomed

DOI: 10.4172/1948-593X-C1-031

The regulatory landscape for the development of biosimilars in the US and EU is dynamic as many of the guidance issued by European Medicines Agency (EMA) have recently undergone revisions and the FDA has issued number of revised guidelines for quality and scientific considerations as well as updated questions and answers documents that lend much needed clarity. FDA has also issued final guidelines for nonproprietary naming of biological products as well as draft interchangeability guidance. This session is designed to provide current status of biosimilar guidelines in the US and EU. The focus will be to identify major updates in order to help sponsors navigate through the complex requirements for the regulatory approval of biosimilars in the US and EU.

Kamali Chance is the Vice President and Head of Global Biosimilars Regulatory Strategy, Biosimilars Center of Excellence. She has over 25 years of work experience in the healthcare industry, including the last 18 years in regulatory affairs/regulatory strategy. She has extensive experience working with the FDA and EMA. She advises pharmaceutical and biotechnology companies in the development of region specific and/or global regulatory strategy for the development of biosimilar products. She has authored/co-authored number of articles on the development of biosimilars and has PhD in Nutrition/Nutritional Biochemistry and Masters of Public Health and Regulatory Affairs Certification.

Email: [email protected]